Compile Data Set for Download or QSAR
Report error Found 172 Enz. Inhib. hit(s) with all data for entry = 12634
TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716376(US20250034108, Example 28)
Affinity DataIC50: 700nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716375(US20250034108, Example 27)
Affinity DataIC50: 800nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716378(US20250034108, Example 29)
Affinity DataIC50: 800nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716356(US20250034108, Example 10)
Affinity DataIC50: 1.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716379(US20250034108, Example 30)
Affinity DataIC50: 1.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716374(US20250034108, Example Rac-27)
Affinity DataIC50: 1.10E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716380(US20250034108, Example 31)
Affinity DataIC50: 1.10E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716353(US20250034108, Example 7)
Affinity DataIC50: 1.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716354(US20250034108, Example 8)
Affinity DataIC50: 1.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716382(US20250034108, Example 33)
Affinity DataIC50: 1.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716387(US20250034108, Example 37)
Affinity DataIC50: 1.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716357(US20250034108, Example 11)
Affinity DataIC50: 1.70E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716373(US20250034108, Example 26)
Affinity DataIC50: 1.80E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716370(US20250034108, Example 24)
Affinity DataIC50: 2.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716371(US20250034108, Example Rac-25)
Affinity DataIC50: 2.20E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716383(US20250034108, Example 34)
Affinity DataIC50: 2.20E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716386(US20250034108, Example Rac-37)
Affinity DataIC50: 2.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716377(US20250034108, Example Rac-29)
Affinity DataIC50: 2.50E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716381(US20250034108, Example 32)
Affinity DataIC50: 2.70E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716362(US20250034108, Example 16)
Affinity DataIC50: 2.80E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716402(US20250034108, Example 52)
Affinity DataIC50: 2.90E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716377(US20250034108, Example Rac-29)
Affinity DataIC50: 3.00E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716337(US20250034108, Example 1)
Affinity DataIC50: 3.10E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716376(US20250034108, Example 28)
Affinity DataIC50: 3.20E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716412(US20250034108, Example 59)
Affinity DataIC50: 3.40E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716414(US20250034108, Example Rac-61)
Affinity DataIC50: 3.40E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716416(US20250034108, Example 62)
Affinity DataIC50: 3.40E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716336(US20250034108, Example Rac-1)
Affinity DataIC50: 3.60E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716409(US20250034108, Example 57)
Affinity DataIC50: 3.60E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716385(US20250034108, Example 36)
Affinity DataIC50: 3.70E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716408(US20250034108, Example Rac-57)
Affinity DataIC50: 3.70E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716417(US20250034108, Example 63)
Affinity DataIC50: 3.80E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716397(US20250034108, Example 47)
Affinity DataIC50: 3.90E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716360(US20250034108, Example 14)
Affinity DataIC50: 4.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716384(US20250034108, Example 35)
Affinity DataIC50: 4.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716355(US20250034108, Example 9)
Affinity DataIC50: 4.10E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716361(US20250034108, Example 15)
Affinity DataIC50: 4.10E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716375(US20250034108, Example 27)
Affinity DataIC50: 4.10E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716358(US20250034108, Example 12)
Affinity DataIC50: 4.20E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716404(US20250034108, Example 54)
Affinity DataIC50: 4.20E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716359(US20250034108, Example 13)
Affinity DataIC50: 4.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716388(US20250034108, Example 38)
Affinity DataIC50: 4.30E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716389(US20250034108, Example 39)
Affinity DataIC50: 4.40E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716405(US20250034108, Example Rac-55)
Affinity DataIC50: 4.50E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716394(US20250034108, Example 44)
Affinity DataIC50: 4.60E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716347(US20250034108, Example 2)
Affinity DataIC50: 4.70E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716362(US20250034108, Example 16)
Affinity DataIC50: 4.80E+3nMMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716395(US20250034108, Example 45)
Affinity DataIC50: 4.80E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716428(US20250034108, Example 75)
Affinity DataIC50: 4.80E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

TargetSodium channel protein type 5 subunit alpha(Human)
Novartis

US Patent
LigandPNGBDBM716365(US20250034108, Example 19)
Affinity DataIC50: 5.00E+3nMAssay Description:To assess peak Nav1.5 current inhibition in an atrial fibrillation-mimicking condition (Nav1.5 IC50 (5 Hz, AF-like rate) (μM)), compounds were first ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 172 total ) | Next | Last >>
Jump to: